Vortex
“As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA
“Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine
Wanda
J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Wanda Awarded US Patent which Extends Protection across the US

London, UK – October 2nd 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces the issue by the U.S. Patent and Trademark Office of a new patent exclusively licensed to its portfolio company, Wanda. The patent will significantly extend protection for the core technology used in Wanda’s software application for remote health and patient management. The patent, titled, “Context-aware prediction in medical systems” is among the technologies developed at UCLA which aim to better assess and predict medical events by defining and using contextual data on top of medical information.

Commenting on the news, NetScientific’s Chief Executive Officer and Chairman of Wanda, Francois R. Martelet said: “We are delighted to announce this strengthening of the IP landscape for Wanda, which represents an important step for Wanda’s organisational development. We believe Wanda’s class leading predictive and behavioural analytics platform acts as a competitive differentiator in the emerging and highly exciting Digital Health sector.”

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found at www.yourwanda.com.